Manish Jain, M.D.January 24, 2022

FDA 483 - Manish Jain, M.D. - January 24, 2022

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Manish Jain, M.D.

Record Details

An FDA inspection of Manish Jain, M.D. revealed significant deficiencies in the conduct of a clinical investigation for a COVID-19 study. The firm failed to adhere to the investigational plan, resulting in incorrect investigational product dosing and improper informed consent procedures. Additionally, issues were noted with inadequate investigational drug disposition records and a failure to maintain accurate and complete case histories.

Company: Manish Jain, M.D.
Inspection Date: January 24, 2022
Product Type: Drugs
Office: Chicago District Office
People: Yuanyuan Li (issuing_officer)
Colleen E. Burke (investigator)
Jeanne J. Thai (investigator)

Open in Dashboard

ID · 89870c40-fc7e-4bd6-ae00-c42ba3d210b3